[1] 曹雅旻, 胡大一. 辛伐他汀对巨噬细胞基质金属蛋白酶-2、9表达及分泌的影响 [J]. 中华心血管病杂志 2004.doi:10.3760/j:issn:0253-3758.2004.07.017
[2] 黄流清, 邵福源. 他汀类药物与痴呆 [J]. 世界临床药物 2003.doi:10.3969/j.issn.1672-9188.2003.09.003
[3] 孙雅菲, 高娟, 檀国军, 杨静, 郭力, SUN Yafei, GAO Juan, TAN Guojun, YANG Jing, GUO Li. 阿托伐他汀对实验性变态反应性脑脊髓炎大鼠TNF-α和iNOS表达的影响 [J]. 中国神经精神疾病杂志 2007.doi:10.3969/j.issn.1002-0152.2007.09.006
[4] 曹滨冬, 李为民, 高成, 沈景霞, 孔一慧, 韩薇, 甘润韬, 耿建强, 李悦, 杨树森, CAO Bin-dong, LI Wei-min, GAO Cheng, SHEN Jing-xia, KONG Yi-hui, HAN Wei, GAN Run-tao, GENG Jian-qiang, LI Yue, YANG Shu-sen. 阿托伐他汀对Lewis大鼠实验性自身免疫性心肌炎作用的研究 [J]. 中国病理生理杂志 2007.doi:10.3321/j.issn:1000-4718.2007.03.027
[5] 牟虹, 陈彤, 何隆, 舒惠荃. 辛伐他汀治疗慢性肾功能不全疗效观察 [J]. 华西医学 2008.doi:10.3969/j.issn.1002-0179.2008.01.081
[6] 袁志忠, 徐成钢, 高春芳, 梅长林. 洛伐他汀对多囊肾囊肿衬里上皮细胞增殖和细胞外基质分泌的影响 [J]. 第二军医大学学报 2006.doi:10.3321/j.issn:0258-879X.2006.01.029
[7] 范珂. 氟伐他汀改善老年收缩期高血压患者脉压的临床观察 [J]. 中国医师杂志 2006.doi:10.3760/cma.j.issn.1008-1372.2006.01.070
[8] 殷跃辉, 石伟, YIN Yue-hui, SHI Wei. 他汀类药物抗心房颤动作用 [J]. 心血管病学进展 2008.doi:10.3969/j.issn.1004-3934.2008.01.043
[9] 梁红锁, 赵宏斌, 马秋野, 胡敏, 李世和, LIANG Hong-suo, ZHAO Hong-bin, MA Qiu-ye, HU Min, LI Shi-he. 普伐他汀对激素性坏死股骨头内Cbfa1表达的影响 [J]. 昆明医学院学报 2006.doi:10.3969/j.issn.1003-4706.2006.02.001
[10] Hansson G K. Inflammation, atherosclerosis and coronary artery disease [J]. New England Journal of Medicine 2005, 352(16).
[11] Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. [J]. The New England journal of medicine 2005, 1(1).
[12] Bonetti P O, Leman L O, Napoli C. Statin effects be yond lipid lowering-are they clinically relevant [J]. European Heart Journal 2003, 24(03).
[13] Walter D H, Rilling K, Bablmann F H. Statin therapy ac celerates reen-dothelization:a novel effect involving mo bilization and incorporation of bone marrow-derived en dothelial progenitor cells [J]. Circulation 2002, 105(25).
[14] Sindemann J, Weigel K, Muller J G. Induction of p53 andinterleukin-8 by HMG-CoA reductase inhibitiors in human coronarysmooth muscle cells [J]. European Heart Journal 1997, 18(06).
[15] Kaneider N C, Reinisch C M, Dunzendorfer S. Induc tion of apoptosis and inhibition of migration of inflammato ry and vascular wallceils by cerivastatin [J]. Atherosclero sis 2001, 158(01).
[16] Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminonen activator inhibitor 1 expression by human vascular smooth muscle and endothelial cells [J]. Arterios cler Thromb Vasc Bio1 2000, 20(02).
[17] Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto-AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Ridker PM. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. [J]. The New England journal of medicine 2009, 18(18).
[18] Hussain H M, Zakria M, Arshad A R. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology [J]. Neurology 2008, 71(24).
[19] Palinski W. Immunomodulation: a new role for statins? [J]. Nature medicine 2000, 12(12).
[20] Kang S, Kim ES, Moon A. Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. [J]. Oncology reports 2009, 5(5).
[21] Bautista LE. Blood pressure-lowering effects of statins: who benefits? [J]. Journal of hypertension 2009, 7(7).
[22] Bautista LE. [J]. Journal of hypertension 2009. |
